Cytotoxic T-lymphocyte antigen-4 blockade in melanoma

Clinical Therapeutics

Volumn 37, Issue 4, 2015, Pages 755-763

  Buchbinder, Elizabeth I ^a   McDermott, David F ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

autoimmunity; checkpoint inhibitor; CTLA4; ipilimumab

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; MONOCLONAL ANTIBODY;

ANTAGONISTS AND INHIBITORS; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; MELANOMA; MOLECULARLY TARGETED THERAPY; PROCEDURES; SECONDARY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CTLA-4 ANTIGEN; HUMANS; IMMUNOTHERAPY; MELANOMA; MOLECULAR TARGETED THERAPY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 84937762747     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.02.003     Document Type: Review

References (55)

1. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Accessed June 23, 2014. http://seer.cancer.gov/statfacts/html/melan.html.
2. M.B. Atkins, M.T. Lotze, and J.P. Dutcher High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993 J Clin Oncol 17 1999 2105 2116
3. P. Bretscher, and M. Cohn A theory of self-nonself discrimination Science 169 1970 1042 1049
4. K.J. Lafferty, and A.J. Cunningham A new analysis of allogeneic interactions Aust J Exp Biol Med Sci 53 1975 27 42
5. R.A. Kroczek, H.W. Mages, and A. Hutloff Emerging paradigms of T-cell co-stimulation Curr Opin Immunol 16 2004 321 327
6. A.H. Sharpe, and G.J. Freeman The B7-CD28 superfamily Nat?Rev Immunol 2 2002 116 126
7. K.J. Scalapino, and D.I. Daikh CTLA-4: a key regulatory point in the control of autoimmune disease Immunol Rev 223 2008 143 155
8. M.F. Krummel, and J.P. Allison CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation J Exp Med 182 1995 459 465
9. M.C. Brunner, C.A. Chambers, and F.K. Chan CTLA-4 mediated inhibition of early events of T cell proliferation J?Immunol 162 1999 5813 5820
10. S.C.L. Gough, L.S. Walker, and D.M. Sansom CTLA-4 gene polymorphism and autoimmunity Immunol Rev 204 2005 102 115
11. T. Lindsten, K.P. Lee, and E.S. Harris Characterization of CTLA-4 structure and expression on human T cells J Immunol 151 1993 3489 3499
12. L. Fong, and E.J. Small Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment J Clin Oncol 26 2008 5275 5283
13. J.P. Allison, A.A. Hurwitz, and D.R. Leach Manipulation of costimulatory signals to enhance antitumor T-cell responses Curr Opin Immunol 7 1995 682 686
14. F.A. Harding, J.G. McArthur, and J.A. Gross CD28-mediated signalling co-stimulates murine T cells and prevents induction of anergy in T-cell clones Nature 356 1992 607 609
15. D.R. Leach, M.F. Krummel, and J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
16. E.D. Kwon, A.A. Hurwitz, and B.A. Foster Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer Proc Natl Acad Sci U S A 94 1997 8099 8103
17. A. Van Elsas, A.A. Hurwitz, and J.P. Allison Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation J Exp Med 190 1999 355 366
18. T. Keler, E. Halk, and L. Vitale Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques J Immunol 171 2003 6251 6259
19. E.J. Small, N.S. Tchekmedyian, and B.I. Rini A pilot trial of CTLA-4 blockade with human anti CTLA-4 in patients with hormone-refractory prostate cancer Clin Cancer Res 13 2007 1810 1815
20. F.S. Hodi, M.C. Mihm, and R.J. Soiffer Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients Proc Natl Acad Sci U S A 100 2003 4212 4217
21. S. Tchekmedyian, J.A. Glasby, and A. Korma MDX-010 (human anti CTLA-4): A phase I trial in malignant melanoma Proc Am Soc Clin Oncol 2002 21 (abstr 56)
22. J.S. Weber, S. O'Day, and W. Urba Phase I/II study of ipilimumab for patient with metastatic melanoma J Clin Oncol 26 2008 5950 5956
23. A.V. Maker, J.C. Yang, and R.M. Sherry Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma J Immunother 29 2006 455 463
24. J.D. Wolchok, B. Neyns, and G. Linette Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomized, double-blind, multicenter, phase 2, dose-ranging study Lancet Oncol 11 2010 155 164
25. S.J. O'Day, M. Maio, and V. Chiarion-Sileni Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Ann Oncol 21 2010 1712 1717
26. L.H. Camacho, S. Antonia, and J. Sosman Phase I/II trial of tremelimumab in patients with metastatic melanoma J Clin Oncol 27 2009 1075 1081
27. O. Hamid, H. Schmidt, and A. Nissan A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma J Transl Med 9 2011 204
28. T.R. Simpson, F. Li, and W. Montalvo-Ortiz Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma J Exp Med 210 2013 1695 1710
29. M.J. Selby, J.J. Engelhardt, and K.A. Quigley Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells Cancer Immunol Res 1 2013 32 42
30. J.D. Wolchok, A. Hoos, and S. O'Day Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria Clin?Cancer Res 15 2009 7412 7420
31. J.S. Weber, K.C. Kahler, and A. Hauschild Management of immune-related adverse events and kinetics of response with ipilimumab J Clin Oncol 30 2012 2691 2697
32. J.D. Wolchok, S.F. Hodi, and J.S. Weber Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma Ann N Y Acad Sci 1291 2013 1 13
33. F.S. Hodi, S.J. O'Day, and D.F. McDermott Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
34. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
35. A. Ribas, R. Kefford, and M.A. Marshall Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma J Clin Oncol 31 2013 616 622
36. K. Margolin, M.S. Ernstoff, and O. Hamid Ipilimumab in patients with melanoma and brain metastasis: an open-label, phase II trial Lancet Oncol 13 2012 459 465
37. J.S. Weber, R. Dummer, and V. de Pril Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma Cancer 119 2013 1675 1682
38. J. Weber, J.A. Thompson, and O. Hamid A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma Clin Cancer Res 15 2009 5591 5598
39. J.A. Blansfield, K.E. Beck, and K. Tran Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer J Immunother 28 2005 593 598
40. S.G. Downey, J.A. Klapper, and F.O. Smith Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade Clin Cancer Res 13 2007 6681 6688
41. F.S. Hodi, S.J. Lee, and D.F. McDermott Multicenter randomized phase II trial of GM-CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608 J Clin Oncol 2013 31 (suppl; abstr CRA 9007)
42. P.A. Prieto, J.C. Jang, and R.M. Sherry CTLA-4 blockade with ipilimumab: long-term follow-up for 177 patients with metastatic melanoma Clin Cancer Res 18 2012 2039 2047
43. D. McDermott, J. Haanen, and T.T. Chen Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20) Ann Oncol 24 2013 2694 2698
44. D. McDermott, C. Lebbe, and F.S. Hodi Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma Cancer Treat Rev 40 2014 1056 1064
45. M.K. Callahan, M.A. Postow, and J.D. Wolchok Immunomodulatory therapy for melanoma: Ipilimumab and beyond Clin in Derm 31 2013 191 199
46. R.R. Ji, S.D. Chasalow, and L. Wang An immune-active tumor microenvironment favors clinical response to ipilimumab Cancer Immunol Immunother 61 2012 1019 1031
47. A.S. Charen, V. Makarov, and T. Merghoub The neoantigen landscape underlying clinical response to ipilimumab J Clin Oncol 32 2014 5s (suppl; abstr 3003)
48. C. Adaniel, J. Rendleman, and D. Polsky Germline genetic determinants of immunotherapy response in metastatic melanoma J Clin Oncol 32 2014 5s (suppl; abstr 3004)
49. A.M. Eggermont, V. Chiarion-Sileni, and J.J. Grob Ipilimumab versus placebo after complete resection of stage II melanoma: initial efficacy and safety results from EORTC 18071 phase III trial J Clin Oncol 32 2014 5s (suppl; abstr LBA9008)
50. J.M. Kirkwood, M.H. Strawderman, and M.S. Ernstoff Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 J Clin Oncol 14 1996 7 17
51. M.A. Postow, M.K. Callahan, and C.A. Barker Immunologic correlates of the abscopal effect in a patient with melanoma N Engl J Med 366 2012 925 931
52. F.S. Hodi, D. Lawrence, and C. Lezcano Bevacizumab plus ipilimumab in patients with metastatic melanoma Cancer Immunol Res 2 2014 632 642
53. A.V. Maker, G.Q. Phan, and P. Attia Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study Ann Surg Oncol 12 2005 1005 1016
54. J.D. Wolchok, H. Kluger, and M.K. Callahan Nivolumab pulse ipilimumab in advanced melanoma N Engl J Med 369 2013 122 133
55. M. Sznol, H.M. Kluger, and M.K. Callahan Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL) J Clin Oncol 32 2014 5s (suppl; abstr LBA9003)